Clinical trial NCT00555594 - References

Corneal Neovascularization — Prospective Study to Determine the Effect of Subconjunctival Bevacizumab (AVASTIN) in Corneal Neovascularization

Citation(s)

•   Ciardella AP, Donsoff IM, Guyer DR, Adamis A, Yannuzzi LA
  Antiangiogenesis agents. Ophthalmol Clin North Am. 2002 Dec;15(4):453-8. Review.
•   Cursiefen C, Seitz B, Dana MR, Streilein JW
  [Angiogenesis and lymphangiogenesis in the cornea. Pathogenesis, clinical implications and treatment options]. Ophthalmologe. 2003 Apr;100(4):292-9. German.
•   Foulks GN, Sanfilippo F
  Beneficial effects of histocompatibility in high-risk corneal transplantation. Am J Ophthalmol. 1982 Nov;94(5):622-9.
•   Foulks GN, Sanfilippo FP, Locascio JA 3rd, MacQueen JM, Dawson DV
  Histocompatibility testing for keratoplasty in high-risk patients. Ophthalmology. 1983 Mar;90(3):239-44.
•   Gan L, Fagerholm P, Palmblad J
  Vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in the regulation of corneal neovascularization and wound healing. Acta Ophthalmol Scand. 2004 Oct;82(5):557-63.
•   Kuwano M, Fukushi J, Okamoto M, Nishie A, Goto H, Ishibashi T, Ono M
  Angiogenesis factors. Intern Med. 2001 Jul;40(7):565-72. Review.
•   Kvanta A, Sarman S, Fagerholm P, Seregard S, Steen B
  Expression of matrix metalloproteinase-2 (MMP-2) and vascular endothelial growth factor (VEGF) in inflammation-associated corneal neovascularization. Exp Eye Res. 2000 Apr;70(4):419-28.
•   Manzano RP, Peyman GA, Khan P, Carvounis PE, Kivilcim M, Ren M, Lake JC, Chévez-Barrios P
  Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin). Br J Ophthalmol. 2007 Jun;91(6):804-7. Epub 2006 Dec 19.
•   Norrby K
  In vivo models of angiogenesis. J Cell Mol Med. 2006 Jul-Sep;10(3):588-612. Review.
•   Presta LG, Chen H, O'Connor SJ, Chisholm V, Meng YG, Krummen L, Winkler M, Ferrara N
  Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 1997 Oct 15;57(20):4593-9.

Prospective Study to Determine the Effect of Subconjunctival Bevacizumab (AVASTIN) in Corneal Neovascularization

Details for clinical trial NCT00555594